Victory Capital Management Inc. Buys 12,484 Shares of Balchem Corporation (NASDAQ:BCPC)

Victory Capital Management Inc. increased its holdings in Balchem Corporation (NASDAQ:BCPC - Free Report) by 10.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,897 shares of the basic materials company's stock after purchasing an additional 12,484 shares during the quarter. Victory Capital Management Inc. owned approximately 0.42% of Balchem worth $22,725,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Norges Bank bought a new stake in Balchem in the 4th quarter worth approximately $70,165,000. GAMMA Investing LLC raised its holdings in shares of Balchem by 20,231.2% during the first quarter. GAMMA Investing LLC now owns 177,288 shares of the basic materials company's stock worth $29,430,000 after purchasing an additional 176,416 shares during the last quarter. Bank of America Corp DE grew its position in Balchem by 120.9% during the fourth quarter. Bank of America Corp DE now owns 156,562 shares of the basic materials company's stock valued at $25,519,000 after buying an additional 85,692 shares during the period. FMR LLC lifted its stake in shares of Balchem by 16.0% in the fourth quarter. FMR LLC now owns 576,994 shares of the basic materials company's stock worth $94,047,000 after buying an additional 79,499 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Balchem by 283.1% during the fourth quarter. BNP Paribas Financial Markets now owns 81,805 shares of the basic materials company's stock worth $13,334,000 after purchasing an additional 60,449 shares during the period. 87.91% of the stock is owned by institutional investors.

Balchem Price Performance

NASDAQ BCPC opened at $153.02 on Tuesday. The company has a 50 day simple moving average of $163.15 and a 200-day simple moving average of $162.67. Balchem Corporation has a 52-week low of $145.70 and a 52-week high of $186.03. The firm has a market capitalization of $4.99 billion, a price-to-earnings ratio of 36.70, a price-to-earnings-growth ratio of 3.30 and a beta of 0.89. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.44 and a quick ratio of 1.40.

Balchem (NASDAQ:BCPC - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The basic materials company reported $1.22 earnings per share for the quarter, missing the consensus estimate of $1.25 by ($0.03). The business had revenue of $250.52 million during the quarter, compared to the consensus estimate of $245.70 million. Balchem had a net margin of 14.16% and a return on equity of 12.01%. The firm's revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.03 earnings per share. Equities research analysts predict that Balchem Corporation will post 4.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BCPC has been the subject of several analyst reports. Wall Street Zen cut shares of Balchem from a "buy" rating to a "hold" rating in a report on Wednesday, May 21st. HC Wainwright set a $180.00 price objective on shares of Balchem and gave the company a "buy" rating in a research note on Monday, April 28th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.